Following preliminary discussion with the FDA, Aldeyra Therapeutics plans to continue advancing reproxalap for dry eye disease, according to a company press release.
In the discussions, the use of reactive aldehyde species (RASP) was decided to be an objective sign for the treatment of dry eye disease, the release said.
RASP, pre-cytokine pro-inflammatory mediators, present in elevated capacities in patients with dry eye disease. In a phase 2a clinical trial, the investigational RASP inhibitor reproxalap demonstrated a reduction in tear RASP levels after 28 days of treatment.
“Representing
Uncategorized